A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of abelacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral anticoagulation

14828ANTHOS-NCT05712200OpenA Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of abelacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral anticoagulation ANT-010NCT05712200IndustrialAdultTreatmentIIIGlobalOtherSidhu, SunjeetMedStar Health and GUMC; Medstar Union Memorial HospitalMCRN - Baltimore EP; MCRN - Electrophysiology2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>